2025
Safety and effectiveness of statins in hospitalized patients with COVID-19: Systematic review and collaborative meta-analysis of randomized controlled trials
Ortega-Paz L, Talasaz A, Sadeghipour P, Rashedi S, Connors J, Angiolillo D, Cavallari L, Jimenez D, Bastidas G, Lorenzi E, Berry L, Hills T, McAuley D, Shah T, Lansky A, Deepti S, Gaitán-Duarte H, Potpara T, Galli M, Dixon D, Piazza G, Lip G, Mehran R, Libby P, Krumholz H, Bikdeli B. Safety and effectiveness of statins in hospitalized patients with COVID-19: Systematic review and collaborative meta-analysis of randomized controlled trials. Thrombosis Research 2025, 255: 109484. PMID: 40992230, DOI: 10.1016/j.thromres.2025.109484.Peer-Reviewed Original ResearchRandomized Controlled TrialsStatin therapyCollaborative meta-analysisHospitalized patientsClinical impactImpact of statin therapyMeta-analysis of randomized controlled trialsCo-treatmentLiver enzyme abnormalitiesExcellent safety profileEffects of statinsCOVID-19 patientsNo significant differenceSafety profileEnzyme abnormalitiesLiver enzymesStatinsSafety outcomesTherapyPatientsCOVID-19 outcomesDisease severitySignificant differenceRandomized participantsSystematic reviewLuspatercept for Patients with Lower-Risk Myelodysplastic Syndromes/Neoplasms: A Systematic Review and Meta-Analysis.
Alhajahjeh A, Link Woite N, Rolles B, Stempel J, Mina A, Mendez L, Kewan T, Podoltsev N, Stahl M, Grimshaw A, Zeidan A, Bewersdorf J. Luspatercept for Patients with Lower-Risk Myelodysplastic Syndromes/Neoplasms: A Systematic Review and Meta-Analysis. Blood Advances 2025 PMID: 40966428, DOI: 10.1182/bloodadvances.2025017611.Peer-Reviewed Original ResearchLower-risk myelodysplastic syndromesLow transfusion burdenTransfusion independenceTransfusion-DependentAdverse eventsTI rateSystematic reviewHematological improvement-erythroidWell-tolerated treatmentFrequent adverse eventsMeta-analysisSerious adverse eventsMeta-analysis aimTransfusion burdenMyelodysplastic syndromeFrontline settingPeripheral edemaSafety profileLuspaterceptPatientsAnemiaHigher RatesEfficacyReviewTransfusionReal-World Safety of Esketamine Nasal Spray: A Comprehensive Analysis Almost 5 Years After First Approval.
Sanacora G, Ahmed M, Brown B, Cabrera P, Doherty T, Himedan M, Kern D, Lim L, Lopena O, Naranjo R, Nuamah I, Sarayani A, Turkoz I, Bowrey H. Real-World Safety of Esketamine Nasal Spray: A Comprehensive Analysis Almost 5 Years After First Approval. American Journal Of Psychiatry 2025, appiajp20240655. PMID: 40926574, DOI: 10.1176/appi.ajp.20240655.Peer-Reviewed Original ResearchSerious adverse eventsReal-world safetyAdverse eventsSafety of esketamine nasal sprayTreatment sessionsSafety of esketaminePatient-monitoring formYears of ageOutpatient treatment sessionsEsketamine administrationSafety profileClinical studiesEsketaminePatient characteristicsDosage patternSafety signalsPostapproval dataSafety dataBlood pressurePatientsMonitoring formsReal-world useIncidenceIncidence of suicideMedication safetyIsatuximab in Relapsed and/or Refractory AL Amyloidosis: Results of a Prospective Phase II Trial (SWOG S1702)
Parker T, Rosenthal A, Sanchorawala V, Landau H, Campagnaro E, Kapoor P, Neparidze N, Girnius S, Hagen P, Scott E, Hoering A, Durie B, Orlowski R. Isatuximab in Relapsed and/or Refractory AL Amyloidosis: Results of a Prospective Phase II Trial (SWOG S1702). Blood 2025 PMID: 40925099, DOI: 10.1182/blood.2024027962.Peer-Reviewed Original ResearchAL amyloidosisProspective phase II trialLight chain (AL) amyloidosisRefractory AL amyloidosisRelapsed AL amyloidosisHematologic response ratePhase 2 trialPhase II trialNT-pro-BNPAnti-CD38 antibodiesPartial responseCardiac involvementII trialRenal involvementMultiple myelomaHematologic responseRenal responseSafety profileAdverse eventsPlasma cellsIsatuximabMulti-centerPatientsResponse rateCardiac responseXevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III Study.
Bourhis J, Licitra L, Burtness B, Psyrri A, Haddad R, Harrington K, Cohen E, Tao Y, Tiscoski K, Matitashvili A, Tahara M, Sukari A, Rutkowski T, Salas S, Nauwelaerts H, Scheerlinck R, Ha N, Schroeder A, Rodriguez-Gutierrez A, Schoenfeld J. Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III Study. Journal Of Clinical Oncology 2025, jco2500272. PMID: 40902136, DOI: 10.1200/jco-25-00272.Peer-Reviewed Original ResearchTreatment-emergent adverse eventsEvent-free survivalUnresectable locally advanced squamous cell carcinomaLocally Advanced Squamous Cell CarcinomaAdvanced squamous cell carcinomaUnresectable LA-SCCHNPhase III studySquamous cell carcinomaHead and neckLA-SCCHNOverall survivalIII studiesCell carcinomaSerious treatment-emergent adverse eventsPlatinum-based chemoradiotherapyProgression-free survivalSecondary end pointsDouble-blindChemoradiotherapySafety profileAdverse eventsPlaceboSCCHNEnd pointsPatientsMillipede88 and Millipede70 catheters for contact aspiration thrombectomy in acute stroke: A multicenter experience.
Hassan A, Haussen D, Al-Bayati A, Dolia J, Grossberg J, Rehman A, Miller S, Colasurdo M, Priest R, Zaidi Syed S, Jumaa M, Bender M, Bhalla T, Herbert R, Matouk C, Arthur A, Nogueira R. Millipede88 and Millipede70 catheters for contact aspiration thrombectomy in acute stroke: A multicenter experience. Interventional Neuroradiology 2025, 15910199251350180. PMID: 40726288, PMCID: PMC12316668, DOI: 10.1177/15910199251350180.Peer-Reviewed Original ResearchMethodsA retrospective analysisContact aspirationAspiration thrombectomyProspective trialsRetrospective analysis of consecutive casesContact aspiration thrombectomyProcedure-related complicationsTreatment of large vessel occlusionCatheter-related complicationsSymptomatic intracranial hemorrhageFirst-line strategyFirst-pass effectLarge vessel occlusionMulticenter experienceFirst-lineIntracranial hemorrhageExcellent recanalizationRecanalization successConsecutive casesCatheter resultsSafety profileOutcome parametersResults26 patientsMechanical thrombectomyDistal emboliBrodalumab: Seven-Year US Pharmacovigilance Report
Lebwohl M, Koo J, Armstrong A, Strober B, Yoon S, Rawnsley N, Goehring Jr. E, Jacobson A. Brodalumab: Seven-Year US Pharmacovigilance Report. Dermatology And Therapy 2025, 15: 3025-3035. PMID: 40730908, PMCID: PMC12454691, DOI: 10.1007/s13555-025-01497-w.Peer-Reviewed Original ResearchSafety profileAdverse eventsInterleukin-17 receptor A antagonistSafety profile of brodalumabPatient years of exposureYears of clinical usageAdverse cardiovascular eventsUS healthcare providersMedical Dictionary for Regulatory ActivitiesStandardized MedDRA QueriesFungal infection ratePlaque psoriasisSystemic therapyTreatment failureSystemic treatmentPatient yearsCardiovascular eventsUS patientsPharmacovigilance reportsMethodsThis reportClinical trialsTreatment durationBrodalumabPharmacovigilance dataPatientsEfficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201
Banerjee S, Van Nieuwenhuysen E, Aghajanian C, D'Hondt V, Monk B, Clamp A, Prendergast E, Oaknin A, Ring K, Colombo N, Holloway R, Rodrigues M, Chon H, Gourley C, Santin A, Thaker P, Gennigens C, Newman G, Salinas E, Youssoufian H, Moore K, Lustgarten S, O'Malley D, Van Gorp T, Grisham R. Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201. Journal Of Clinical Oncology 2025, 43: 2782-2792. PMID: 40644648, PMCID: PMC12393057, DOI: 10.1200/jco-25-00112.Peer-Reviewed Original ResearchConceptsLow-grade serous ovarian cancerRecurrent low-grade serous ovarian cancersRandomized phase 3 studySerous ovarian cancerWild-type cohortAdverse eventsMedian durationOvarian cancerSafety profileMedian duration of responseTreatment-related adverse eventsProgression-free survivalDuration of responsePrimary analysisIndependent central reviewOpen-label studyElevated creatine phosphokinaseConfirmed ORRWeeks' monotherapyCombination regimenPlatinum chemotherapyMutation statusCentral reviewMEK inhibitorsPatientsCompletion of phase 2b trial of etranacogene dezaparvovec gene therapy in patients with hemophilia B over 5 years
von Drygalski A, Gomez E, Giermasz A, Castaman G, Key N, Lattimore S, Leebeek F, Miesbach W, Recht M, Monahan P, Le Quellec S, Pipe S. Completion of phase 2b trial of etranacogene dezaparvovec gene therapy in patients with hemophilia B over 5 years. Blood Advances 2025, 9: 3543-3552. PMID: 40188458, PMCID: PMC12275190, DOI: 10.1182/bloodadvances.2024015291.Peer-Reviewed Original ResearchAdeno-associated virus serotype 5Etranacogene dezaparvovecHemophilia BRecombinant adeno-associated virus serotype 5FIX inhibitor developmentLiver-specific promoterPost-administrationSelf-administered infusionsSevere hemophilia BMulti-center trialYears post-administrationBleeding episodesOpen-labelSingle-doseSecondary endpointsIntravenous doseSingle-armGene therapyThrombotic complicationsYears post-treatmentSafety profileClinically significant elevationsAdverse eventsBleeding frequencyNeutralizing antibodiesCurrent Trends and Future Directions of the Dual 1550‐nm Erbium Glass Fiber and 1927‐nm Thulium Fiber Non‐Ablative Fractional Laser System
Friedman P, Dover J, Chapas A, Jacobson A. Current Trends and Future Directions of the Dual 1550‐nm Erbium Glass Fiber and 1927‐nm Thulium Fiber Non‐Ablative Fractional Laser System. Lasers In Surgery And Medicine 2025, 57: 561-570. PMID: 40635144, DOI: 10.1002/lsm.70043.Peer-Reviewed Original ResearchConceptsMechanism of actionSystemic mechanism of actionExpert consensusPersonalized treatment approachesFitzpatrick skin typeFractional laser systemActinic keratosesSafety profilePigmented lesionsTreatment approachesEsthetic medicineSkin concernsSkin typeSkin conditionsStandard protocolLaser systemDyschromiaSkin agingOutcomes of immune checkpoint inhibitor rechallenge in relapsed/refractory Hodgkin lymphoma
Nishimura Y, Han Y, Toumeh N, Janda G, Fujiwara Y, Durani U, Nowakowski G, Paludo J, Ansell S, Abeykoon J. Outcomes of immune checkpoint inhibitor rechallenge in relapsed/refractory Hodgkin lymphoma. Blood Neoplasia 2025, 2: 100134. PMID: 40809195, PMCID: PMC12346057, DOI: 10.1016/j.bneo.2025.100134.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsProgression-free survivalImmune checkpoint inhibitors rechallengeOverall response rateHodgkin lymphomaAdverse eventsICI rechallengeComplete responseResponse rateMedian progression-free survivalImmune-related adverse eventsRelapsed/Refractory Hodgkin LymphomaPooled response rateConfidence intervalsClassical HLICI therapyR/R HLCheckpoint inhibitorsAny-gradeSystematic literature searchCR ratePatient selectionSafety profileRechallengePreferred Reporting ItemsDeep Dive into Targeted Therapies: Understanding IDH1-Mutant AML Treatments [Podcast]
Zeidan A, DiNardo C. Deep Dive into Targeted Therapies: Understanding IDH1-Mutant AML Treatments [Podcast]. Blood And Lymphatic Cancer Targets And Therapy 2025, 15: 69-75. PMID: 40630560, PMCID: PMC12235440, DOI: 10.2147/blctt.s549780.Peer-Reviewed Original ResearchAcute myeloid leukemiaTargeted therapyIDH1 inhibitorsProlonged duration of remissionRefractory acute myeloid leukemiaIDH1-mutated acute myeloid leukemiaProlonged durationOral targeted agentsDuration of remissionAcute myeloid leukemia treatmentQT interval prolongationIndividualized therapy selectionClinical trial studyCombination regimensIntensive chemotherapyAML treatmentInterval prolongationUnfit patientsMyeloid leukemiaClinical benefitTherapeutic optionsSafety profileTherapy selectionDifferentiation syndromeToxicity managementA Review of the Evidence Surrounding Popular Cognitive Enhancers
Draghmeh K, Elmarasi M, Fuehrlein B. A Review of the Evidence Surrounding Popular Cognitive Enhancers. Current Psychopharmacologye 2025, 13 DOI: 10.2174/0122115560363501250609121229.Peer-Reviewed Original ResearchEfficacy and safety of oral decitabine/cedazuridine in the chronic myelomonocytic leukaemia subpopulations from phase 2 and 3 studies
Savona M, Odenike O, Roboz G, Amin H, DeZern A, Griffiths E, Dao K, Zeidan A, Bhatnagar B, Buckstein R, Leber B, Keating M, Ball S, Oganesian A, Sano Y, Keer H, Garcia‐Manero G. Efficacy and safety of oral decitabine/cedazuridine in the chronic myelomonocytic leukaemia subpopulations from phase 2 and 3 studies. British Journal Of Haematology 2025, 207: 432-444. PMID: 40524338, PMCID: PMC12378960, DOI: 10.1111/bjh.20203.Peer-Reviewed Original ResearchChronic myelomonocytic leukemiaCMML-specific prognostic scoring systemTreating chronic myelomonocytic leukemiaRed blood cell transfusionTransformation-free survivalPrognostic scoring systemBlood cell transfusionHigh-risk diseasePotential prognostic factorsAssociated with survivalDNA methyltransferase inhibitorTransfusion independenceIntermediate-2Median survivalCell transfusionMyelodysplastic syndromePrognostic factorsMyelomonocytic leukemiaSafety profileProspective studyDecitabine/cedazuridineMethyltransferase inhibitorRandomised trialsPatientsResponse rateORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor–Mutated Advanced Non–Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib
Riess J, de Langen A, Ponce S, Goldberg S, Piotrowska Z, Goldman J, Le X, Cho B, Yoneshima Y, Ambrose H, Cavazzina R, Tang K, Lau J, Yu H. ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor–Mutated Advanced Non–Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib. JCO Precision Oncology 2025, 9: e2400818. PMID: 40466026, DOI: 10.1200/po-24-00818.Peer-Reviewed Original ResearchConceptsAdvanced non-small cell lung cancerNon-small cell lung cancerCell lung cancerLung cancerEpidermal growth factor receptor alterationsFirst-line osimertinibSafety of osimertinibProgression-free survivalDuration of responseNovel drug combinationsData cutoffPartial responseOsimertinib resistanceRisk-benefit analysisOverall survivalReceptor alterationsDiscontinued treatmentInvestigator assessmentClinical benefitNecitumumabSafety profileOsimertinibReport final resultsAdverse eventsDrug combinationsLong-term Efficacy and Safety of Lifileucel Tumor-infiltrating Lymphocyte (TIL) Cell Therapy in Patients with Advanced Melanoma: A 5-year Analysis of the C-144-01 Study.
Medina T, Chesney J, Kluger H, Hamid O, Whitman E, Cusnir M, Thomas S, Wermke M, Domingo-Musibay E, Phan G, Kirkwood J, Larkin J, Weber J, Graf Finckenstein F, Chou J, Gastman B, Wu X, Fiaz R, Sarnaik A, Curti B, Kim K, Daniels G, Wilson M, Lee S, Puzanov I, Harker-Murray A, Logan T, Simon J, Thomas I, Schuler-Thurner B, Moritz R, Hassel J, Grigoliet G, Arance A, Rubio B, Rodriguez J, Berrocal A, de Sanmamed M, Arkenau H, Evans T, Corrie P, Dalle S, Bedane C, Olah J, Orcurto A. Long-term Efficacy and Safety of Lifileucel Tumor-infiltrating Lymphocyte (TIL) Cell Therapy in Patients with Advanced Melanoma: A 5-year Analysis of the C-144-01 Study. Journal Of Clinical Oncology 2025, 101200jco2500765. PMID: 40454684, DOI: 10.1200/jco-25-00765.Peer-Reviewed Original ResearchTumor-infiltrating lymphocytesOverall survivalLong-term efficacyCell therapyMedian duration of responseLow tumor burdenMedian overall survivalDuration of responseTumor burden reductionLong-term safety concernsBRAF/MEK inhibitorsAdvanced melanomaBrain metastasesImmune checkpointsTumor burdenMedian durationSafety profileAdverse eventsTreatment optionsInterleukin-2Follow-upLong-term benefitsOverall populationPatientsCutoff dateSWOG S2302, PRAGMATICA-LUNG: A pragmatic trial designed to increase participant representation.
Reckamp K, Redman M, Dragnev K, Khalil M, Henick B, Moon J, Ahmadzai P, LeBlanc M, Carrizosa D, Herbst R, Blanke C, Gray J. SWOG S2302, PRAGMATICA-LUNG: A pragmatic trial designed to increase participant representation. Journal Of Clinical Oncology 2025, 43: 11016-11016. DOI: 10.1200/jco.2025.43.16_suppl.11016.Peer-Reviewed Original ResearchNon-small cell lung cancerAdvanced non-small cell lung cancerStandard of careOverall survivalPD-(L)1Randomized phase III trialPhase II Randomized StudyPlatinum-based therapyTreated with immunotherapyPhase III trialsCell lung cancerYears of ageInhibitor therapyIII trialsStudy drugConcomitant medicationsOS endpointSafety profileToxicity profileAdverse eventsEffective therapyLung cancerBlack patientsReal-world practiceLaboratory assessmentStudy EV-103 cohort H: Neoadjuvant treatment with enfortumab vedotin (EV) monotherapy in cisplatin (cis)-ineligible patients (pts) with muscle invasive bladder cancer (MIBC)—3-year efficacy results.
Mar N, Petrylak D, Hoimes C, Rosenberg J, Flaig T, Gourdin T, Barata P, Henry E, Bilen M, George S, Rao S, Assikis V, Burgess E, Lewis B, Srinivas S, Gorla S, Meng C, Zhu Y, O'Donnell P. Study EV-103 cohort H: Neoadjuvant treatment with enfortumab vedotin (EV) monotherapy in cisplatin (cis)-ineligible patients (pts) with muscle invasive bladder cancer (MIBC)—3-year efficacy results. Journal Of Clinical Oncology 2025, 43: 4583-4583. DOI: 10.1200/jco.2025.43.16_suppl.4583.Peer-Reviewed Original ResearchMedian event-free survivalPathological complete responseEvent-free survivalInvestigator assessmentEnfortumab vedotinEfficacy resultsOS ratesNeoadjuvant treatmentSafety profileFollow-upPathologic complete response ratePelvic lymph node dissectionEvent-free survival rateAntitumor activityLong-term follow-upCentral pathology reviewEstimated OS ratesNeoadjuvant treatment optionsLymph node dissectionMedian Follow-UpPhase 3 trialCT2-T4aN0M0Median OSConsistent with prior reportsComplete responseMore than just another IDH inhibitor: Insights from the HMPL-306 phase 1 trial
Getz T, Bewersdorf J. More than just another IDH inhibitor: Insights from the HMPL-306 phase 1 trial. Med 2025, 6: 100600. PMID: 40516517, DOI: 10.1016/j.medj.2025.100600.Peer-Reviewed Original ResearchEffect of prior treatment (tx) on the clinical activity of imetelstat (IME) in transfusion-dependent (TD) patients (pts) with erythropoiesis-stimulating agent (ESA), relapsed or refractory (R/R)/ineligible lower-risk myelodysplastic syndromes (LR-MDS).
Komrokji R, Santini V, Zeidan A, Sekeres M, Fenaux P, Raza A, Mittelman M, Thepot S, Buckstein R, Germing U, Madanat Y, Diez-Campelo M, Valcárcel D, Jonasova A, Shah S, Xia Q, Sun L, Navada S, Savona M, Platzbecker U. Effect of prior treatment (tx) on the clinical activity of imetelstat (IME) in transfusion-dependent (TD) patients (pts) with erythropoiesis-stimulating agent (ESA), relapsed or refractory (R/R)/ineligible lower-risk myelodysplastic syndromes (LR-MDS). Journal Of Clinical Oncology 2025, 43: 6569-6569. DOI: 10.1200/jco.2025.43.16_suppl.6569.Peer-Reviewed Original ResearchLower-risk myelodysplastic syndromesErythropoiesis-stimulating agentsHematological improvement-erythroidRBC-TIHypomethylating agentsTransfusion burdenClinical activityInternational Working GroupTransfusion-DependentTransfusion reductionData cutoff dateRBC transfusion independenceFirst-in-classPooled dataEffect of prior treatmentHb riseMyelodysplastic syndromeMedian durationPhase 2/3Clinical benefitSafety profileLenalidomideActive dosesImetelstatEfficacy data
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply